| Literature DB >> 35885773 |
Masami Mukai1,2, Katsuhiko Ogasawara3.
Abstract
Many medical information standards are not widely used in Japan, and this hinders the promotion of the use of real-world data. However, the complex intertwining of many factors hindering the dissemination of medical information standards makes it difficult to solve this problem. This study analyzed and visualized relationships among factors that inhibit the dissemination of medical information standards. Five medical informatics experts affiliated with universities and hospitals were interviewed about the factors that hinder the dissemination of medical information standards in Japan. The presented factors were analyzed using the interpretive structural modeling (ISM) method and the decision-making trial and evaluation laboratory (DEMATEL) method. We found that "legislation" and "reliability" were important inhibiting factors for the dissemination of medical information standards in Japan. We also found a six-layered structure in which "reliability" was satisfied when "legislation" was in place and "expectations" and "personal information" were resolved. The DEMATEL analysis indicated the relationships and classifications of factors hindering the dissemination of medical information standards. Since the adoption of medical information standards does not directly lead to revenue for medical institutions, it is possible to meet the "expectation" of improving the quality of medical care by ensuring "legislation" and "reliability", that is, ensuring the dependability of medical treatment. The results of this study visually show the structure of the factors and will help solve the problems that hinder the effective and efficient spread of standards. Solving these problems may support the efficient use of real-world data.Entities:
Keywords: DEMATEL; ISM; inhabitant factor; real-world data (RWD); standards
Year: 2022 PMID: 35885773 PMCID: PMC9321384 DOI: 10.3390/healthcare10071248
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
Figure 1Flowchart of the analysis steps.
Extracted factors (excerpts).
| Experts | Factors |
|---|---|
| Administrative institutions and researchers | No incentive for standardization |
| National research institute and researchers | Vendors’ responses are mixed |
Definition of elements.
| Elements | Definition (Contents) |
|---|---|
| Legislation | The need for legislation and guideline maintenance as an environment when using standardization technology in medicine |
| Quality of healthcare | Expectations for the improvement of medical care quality and treatment through standardized technology or assurance of medical care quality |
| Medical expenses | The impact of standardized technology use on healthcare costs, or bearing the costs for medical care and treatment using technology |
| Reliability | Ensuring confidence in medical and medical practice based on standardized technology and its methods |
| Technological interest | Interest in and understanding of standardization technologies and the means to increase this interest |
| Liability | Organizing the breakdown of responsibilities for medical care and treatment that use standardized technology |
| Assurance | Assurance that the system reflects standardized technology, technical response to the fact that the standardized technology itself is being updated, and organization of the maintenance scope |
| Expectations | Improvement of the medical care quality by the use of standardization technology in medical care, and motivation to use standardization technology in medical care |
| Knowledge availability | Understanding the standardization technology, and experience of examples of implementation in other fields and its necessity |
| Personal information | Organizing the handling of personal information as data when developing standardization technologies, and the risks to personal and private information when using standardization technologies |
Interpretive structural modeling relational matrix.
| Legislation | Quality of Healthcare | Medical Expenses | Reliability | Technological Interest | Liability | Assurance | Expectations | Knowledge Availability | Personal Information | |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 0 | 0 | 3 | 0 | 1 | 4 | 4 | 1 | 0 | 2 |
|
| 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 4 | 0 | 2 | 0 | 0 | 0 | 0 |
Figure 2Interpretive structural modeling hierarchy diagram.
Indicators of inhibiting factors identified by the decision-making trial and evaluation laboratory method.
| Inhibition Factor | Affected Degree (a) | Influence Degree (b) | Centrality (a + b) | Causality (b − a) | |
|---|---|---|---|---|---|
| (1) | legislation | 0 | 0.433 | 0.433 | 0.433 |
| (2) | quality of healthcare | 0.076 | 0.071 | 0.147 | −0.005 |
| (3) | medical expenses | 0.071 | 0 | 0.071 | −0.071 |
| (4) | reliability | 0.29 | 0 | 0.29 | −0.29 |
| (5) | technological interest | 0.077 | 0.136 | 0.213 | 0.059 |
| (6) | liability | 0.153 | 0 | 0.153 | −0.153 |
| (7) | assurance | 0.133 | 0.047 | 0.18 | −0.086 |
| (8) | expectations | 0.024 | 0.078 | 0.102 | 0.054 |
| (9) | knowledge availability | 0.129 | 0.092 | 0.221 | −0.037 |
| (10) | personal information | 0.047 | 0.142 | 0.189 | 0.095 |
Figure 3Graphs with Centrality and causality of elements identified by the decision-making trial and evaluation laboratory method. The meanings of the numbers in the figure are shown in Table 4.